Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
Keun-Sik Hong, Oh Young Bang, Jong-Ho Park, Jin-Man Jung, Sang-Hun Lee, Tae-Jin Song, Hyo Suk Nam, Hee-Kwon Park, Keun-Hwa Jung, Sung Hyuk Heo, Jaseong Koo, Kyung-Ho Yu, Kwang-Yeol Park, Chi Kyung Kim, Hong-Kyun Park, Jiyoon Lee, Juneyoung Lee, Woo-Keun Seo
J Stroke. 2023;25(2):242-250.   Published online 2023 Apr 11     DOI: https://doi.org/10.5853/jos.2022.02957
Citations to this article as recorded by Crossref logo
Are We Using Ezetimibe As Much As We Should?
Antonis A Manolis, Theodora A Manolis, Dimitri P Mikhailidis, Antonis S Manolis
Biomarker Insights.2024;[Epub]     CrossRef
Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study
Sergio Cinza-Sanjurjo, Vivencio Barrios, David Fierro-González, Jose Polo-García, Vicente Pallarés-Carratalá, Arquimedes Gasparotto Junior
Cardiovascular Therapeutics.2024;[Epub]     CrossRef
In patients with atherosclerotic cardiovascular disease, is moderately intensive statin plus ezetimibe as effective as high dosed statin therapy?
Megan Doyle, Deborah Midgley, Joanna Wu
Evidence-Based Practice.2024;[Epub]     CrossRef